SB Investment Advisers Cuts Relay Therapeutics Holding To 21.9 Million Shares From 27.9 Million

Coupang made up about 65% of the disclosed portfolio, which fell in value to $6.2 billion from $7.7 billion.

Share
SB Investment Advisers Cuts Relay Therapeutics Holding To 21.9 Million Shares From 27.9 Million

SB Investment Advisers, the SoftBank Vision Fund arm that reports its US stock holdings, cut its Relay Therapeutics position to 21.9 million shares from 27.9 million in the third quarter. Its quarterly SEC holdings report filed Tuesday also showed a smaller Compass stake, with Coupang accounting for about 65% of the disclosed portfolio.

Relay And Compass Get Smaller

Relay's share count was about 78% of its prior-quarter level. The position's reported value fell to $395.4 million from $522.1 million, leaving it at about 6% of the portfolio at quarter-end.

SB Investment Advisers reduced its Compass holding to 20.5 million shares from 21.5 million. That position was valued at $181.9 million, down from $265.2 million, and represented 3% of the disclosed holdings.

Both positions shrank in share count as well as reported value. The share counts establish the trims; the dollar figures measure what the remaining holdings were worth at quarter-end.

Coupang Dominates The $6.2 Billion Portfolio

The disclosed US stock portfolio stood at $6.2 billion across nine positions on September 30, down from $7.7 billion at the end of June.

Coupang remained the largest holding: 289.5 million shares valued at $4 billion. Its roughly 65% portfolio weight put it well ahead of Grab, which accounted for about 20% of the third-quarter total.

The quarterly report, known as a 13F, covers long positions in US-listed stocks and disclosed options. Cash, bonds, short positions and non-US holdings sit outside that reporting scope.

The concentration figures describe SB Investment Advisers' disclosed US stock portfolio, not the Vision Fund's entire pool of investments.

Sources